WO1992014749A1 - Thyroid-derived chondrocyte-stimulating factor - Google Patents
Thyroid-derived chondrocyte-stimulating factor Download PDFInfo
- Publication number
- WO1992014749A1 WO1992014749A1 PCT/US1992/000993 US9200993W WO9214749A1 WO 1992014749 A1 WO1992014749 A1 WO 1992014749A1 US 9200993 W US9200993 W US 9200993W WO 9214749 A1 WO9214749 A1 WO 9214749A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tdcsf
- antibodies
- conjugate
- chondrocytes
- cells
- Prior art date
Links
- 210000001685 thyroid gland Anatomy 0.000 title claims abstract description 20
- 210000001612 chondrocyte Anatomy 0.000 claims abstract description 41
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000004202 carbamide Substances 0.000 claims abstract description 22
- 210000002950 fibroblast Anatomy 0.000 claims abstract description 21
- 230000012010 growth Effects 0.000 claims abstract description 15
- 239000007943 implant Substances 0.000 claims abstract description 15
- 210000000845 cartilage Anatomy 0.000 claims abstract description 14
- 238000000338 in vitro Methods 0.000 claims abstract description 12
- 230000004936 stimulating effect Effects 0.000 claims abstract description 11
- 210000002966 serum Anatomy 0.000 claims abstract description 9
- 230000008439 repair process Effects 0.000 claims abstract description 6
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 36
- 210000004027 cell Anatomy 0.000 claims description 31
- 239000011780 sodium chloride Substances 0.000 claims description 26
- 229920002684 Sepharose Polymers 0.000 claims description 20
- 210000001519 tissue Anatomy 0.000 claims description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 13
- 239000002244 precipitate Substances 0.000 claims description 13
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 11
- 239000006228 supernatant Substances 0.000 claims description 11
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 10
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 8
- 239000012636 effector Substances 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 230000000638 stimulation Effects 0.000 claims description 7
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 5
- 102000004142 Trypsin Human genes 0.000 claims description 4
- 108090000631 Trypsin Proteins 0.000 claims description 4
- 230000002378 acidificating effect Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000012588 trypsin Substances 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 3
- 239000003053 toxin Substances 0.000 claims description 3
- 231100000765 toxin Toxicity 0.000 claims description 3
- 239000011159 matrix material Substances 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000029087 digestion Effects 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000003638 chemical reducing agent Substances 0.000 abstract description 8
- 238000001727 in vivo Methods 0.000 abstract description 3
- 201000008482 osteoarthritis Diseases 0.000 abstract description 2
- 230000007547 defect Effects 0.000 abstract 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 46
- 230000000694 effects Effects 0.000 description 42
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 18
- 238000003556 assay Methods 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 9
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 9
- 239000012506 Sephacryl® Substances 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 238000010828 elution Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241000283690 Bos taurus Species 0.000 description 6
- 102000055006 Calcitonin Human genes 0.000 description 6
- 108060001064 Calcitonin Proteins 0.000 description 6
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 6
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 6
- 229960004015 calcitonin Drugs 0.000 description 6
- 238000001502 gel electrophoresis Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 102400001368 Epidermal growth factor Human genes 0.000 description 4
- 101800003838 Epidermal growth factor Proteins 0.000 description 4
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
- 210000002808 connective tissue Anatomy 0.000 description 4
- 229940116977 epidermal growth factor Drugs 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 4
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- 229930182566 Gentamicin Natural products 0.000 description 3
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 3
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000005349 anion exchange Methods 0.000 description 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000002523 gelfiltration Methods 0.000 description 3
- 229960002518 gentamicin Drugs 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 229940104230 thymidine Drugs 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 2
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 2
- 241000906034 Orthops Species 0.000 description 2
- 102000009843 Thyroglobulin Human genes 0.000 description 2
- 108010034949 Thyroglobulin Proteins 0.000 description 2
- 101710162629 Trypsin inhibitor Proteins 0.000 description 2
- 229940122618 Trypsin inhibitor Drugs 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008473 connective tissue growth Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000006167 equilibration buffer Substances 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229960002175 thyroglobulin Drugs 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- IPDRTIBDOPMMIQ-VAOFZXAKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)-2-methyloxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@]1(C)O[C@H](CO)[C@@H](O)C1 IPDRTIBDOPMMIQ-VAOFZXAKSA-N 0.000 description 1
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- UNXHWFMMPAWVPI-QWWZWVQMSA-N D-threitol Chemical compound OC[C@@H](O)[C@H](O)CO UNXHWFMMPAWVPI-QWWZWVQMSA-N 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 235000010624 Medicago sativa Nutrition 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101100522110 Oryza sativa subsp. japonica PHT1-10 gene Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 101100522109 Pinus taeda PT10 gene Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000004349 growth plate Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000001426 native polyacrylamide gel electrophoresis Methods 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000012465 retentate Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000012488 skeletal system development Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000012799 strong cation exchange Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000003211 trypan blue cell staining Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000012784 weak cation exchange Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/854—Glands
Definitions
- the invention relates to a factor useful for cartilage repair including in vitro stimulation of chondrocytes and synovial fibroblasts. More particu ⁇ larly, it concerns a factor which can be isolated from thyroid tissue which stimulates both synovial fibroblasts and chondrocytes under serum-free conditions and which is stabilized by reducing agents that reduce disulfides.
- TGF- ⁇ transforming growth factor ⁇
- PDGF platelet derived growth factor
- IGF-I and IGF-II insulin-like growth factors types I and II
- FGF acidic and basic fibroblast growth factors
- EGF epidermal derived growth factor
- T 3 3,3* ,5'-triiodo- 1,3-L-thyronine
- T 4 thyroxine
- calcitonin are known to affect connective tissue metabolism. However, their effects are generally directed to immature cells.
- T-, and T. are important for growth and maturation of the epithelial cartilage secondary ossification, and generalized skeletal development; calcitonin increases hypertrophy and maturation of embryonic and growth plate cartilage, but resting cartilage is unresponsive to calcitonin.
- Acidic FGF is eluted at 1 M NaCl under comparable conditions and basic FGF is eluted at 1.6 M NaCl under comparable conditions (Lobb, R.R. , et al., Anal Bioche (1986) 154:1-14.) The nature of this activity was not further characterized.
- the invention provides a complex of high molecular weight which can be at least partially dissociated by 8M urea into active subunits. Both the complex and the dissociated subunits stimulate chondro ⁇ cyte and synovial fibroblast growth under serum-free conditions in vitro and can thus be used as a substitute for serum in the culture of these cells. Furthermore, the complex or its dissociated portions are useful in the in vitro development of implants for medical use, and are useful in vivo in the treatment of connective tissue conditions which reguire the enhancement of connective tissue growth and/or the integration of grafts or implants into bone or cartilage.
- the invention is directed to a high molecular weight proteinaceous complex with the ability to stimulate chondrocyte or synovial fibroblast growth under serum-free conditions in vitro.
- the complex can be at least partially dissociated by 8 M urea into portions of the complex which retain this activity but which are also of high molecular weight (>500 kd) .
- the invention is also directed to these subunits.
- the complex and its subunits, collectively called thyroid- derived chondrocyte stimulating factor (TDCSF) are stabilized by reducing agents that are capable of reducing disulfide bonds, such as ercaptoethanol and dithiothreitol.
- the factor is (the factor is) inactivated by treatment with acetic acid for one hour at 4°C, and by treatment by trypsin.
- the complex and its subunits are also inactivated by heating to 100°C for one hour but not by heating to 60°C for one hour.
- the factor can be eluted from heparin-Sepharose at 0.5 M NaCl.
- the invention is directed to pharmaceutical compositions, including implant compositions containing this factor and to methods for treating diseases or degenerative conditions of the connective tissue system with the factor or its compositions.
- the invention is directed to a method to obtain the factor from thyroid tissue and to methods to use the factor in vitro in the development of implant compositions or as a serum substitute in the growth of chondrocytes or fibroblasts.
- the invention is also directed to antibodies specifically immunoreactive with the factor, and to conjugates of the factor with label or other effector agents, and to the uses of these antibodies and conjugates.
- Figure 1 shows the elution pattern for the factor of the invention from a Sephacryl S-300 column.
- Figure 2 shows an elution pattern analogous to that of Figure 1, but with the inclusion of 5 M urea.
- Figure 3 shows an elution pattern analogous to that of Figures 1 and 2, but in the presence of 8 M urea.
- Figure 4 shows the results of nonreducing native gel electrophoresis of the excluded volume shown in the elution patterns of Figures 1, 2 and 3.
- the invention factor can be isolated from thyroid tissue and is provided as a high molecular weight complex of >500 kd.
- the complex can be at least partially dissociated by 8 M urea into subunits which retain the activity of the complex, and are also of high molecular weight.
- the "factor" (TDCSF) of the invention includes both the complex in undisso- ciated form and the dissociated subunits, as described above. Both of these manifestations of the factor are capable of stimulating the growth of synovial fibroblasts and adult articular chondrocytes under serum-free conditions.
- the factor can be obtained from thyroid tissue by subjecting the 40-80% ammonium sulfate fraction from the tissue homogenate supernatant to chro atography on heparin-Sepharose.
- the factor elutes at approximately 0.5 M NaCl and is dialyzed against DPBS containing 1 mM 2-ME before testing. Any samples to be stored are dialyzed against water containing 1 mM 2-ME and freeze- dried.
- the factor can be further purified by gel filtration. In the gel filtration treatment, the factor is excluded from a Sephacryl S-300 column with a molecular weight cutoff of 10 -10 daltons. The factor can be further purified, if desired, using native gel electrophoresis.
- the complex form of the factor is at least partially dissociated by 8 M urea into subunits which retain the characteristics of the complex listed below.
- the factor is acidic—i.e., it does not bind to weak (carboxymethylcellulose) or strong (mono-S) cationic exchange columns at pH 7.2, but does bind to weak (DEAE cellulose) or strong (mono-Q) anion exchange columns at pH 7.2 under the following conditions: the candidate is applied to a column containing the anion or cation exchanger in the presence of 1/10 Dulbecco's phosphate-buffered saline (DPBS) at pH 7.2 in the presence of 1 mM ⁇ -mercaptoethanol (2-ME) .
- DPBS Dulbecco's phosphate-buffered saline
- 2-ME 1 mM ⁇ -mercaptoethanol
- the ion exchange resin has been preeguilibrated in 1/10 DPBS.
- the presence or absence of the candidate in the flowthrough volume is then assessed.
- the ion exchange resins can then be eluted in salt gradient to verify presence or absence of the candidate
- articular chondrocytes are prepared by collecting bovine cartilage from radiocarpal joints and dissociated in 20 ml Dulbecco's Modified Eagle's Medium (DMEM) containing gentamicin (50 ⁇ g/ml) and bacterial collagenase (CLS-II and CLS-IV) , at a concentration of 0.5 g/ml each (Kohatsu, N.D., et al., "Transactions of the 27th Annual Meeting of the Orthopedic Research Society” (1981), 6.:214). The dissociated cells are collected by centrifugation at 450 g for 15 minutes and washed twice in DPBS and once in DMEM.
- DMEM Dulbecco's Modified Eagle's Medium
- CLS-II and CLS-IV bacterial collagenase
- Single cells are obtained by Nytex filtration and cell numbers determined by counting in a hemacytometer, and viability is assessed by Trypan Blue dye exclusion. After dilution in serum- free medium, the cells are dispersed in 16-mm plastic wells (24 wells/plate) at a density of 2 x 10 5 cells/cm_"> and incubated at 7% C0 2 , 100% humidity, at 37°C.
- the medium consists of DMEM and Ham's F-12 medium mixed at a ratio of 1:1; the sulfate concentration of this mixture is 78.6 mg/1.
- Gentamicin 50 ⁇ g/ml
- selenium (2 x 10 —8 M)
- a lipid supplement (Bettger, .J., et al. , Proc Natl Acad Sci USA (1981) 21:5588-5592) were also added.
- These lipids are transferred to the medium as liposomes prepared just prior to use, as described in the Jones and Smith paper referenced above ( J Orthop Res (1990) 8.:227- 233).
- the stock liposomes Prior to use, the stock liposomes are diluted 1:1 in DMEM and the mixture is sonicated for 3 minutes at 4°C under nitrogen and sterilized by ultrafiltration (0.22 ⁇ m) .
- Culture dishes are treated with poly-D-lysine (0.1 mg/ml) before plating the cells under these serum-free conditions; polylysine is removed by repeated rinsing with sterile distilled water (3 x 1 ml/well) .
- the foregoing culture medium is changed every three days and gentamicin (50 ⁇ g/ml) is maintained in all culture conditions.
- Each well contains 0.5 ml of medium.
- tritiated thymidine methyl-3H-thymidine, 27.7 Ci/g
- the wells are incubated in the presence of the labeled thymidine for 72 hours at 37°C.
- the medium is then removed from each well and the cell layer gently rinsed twice with 1 ml DPBS to remove unincorporated thymidine.
- the cells are solubilized by addition of 0.5 ml 1 N sodium hydroxide and heating at 60°C for one hour. The solubilized samples are then counted.
- the TDCSF of the invention stimulates the growth of synovial fibroblasts.
- the ability of the factor to stimulate the growth of synovial fibroblasts is assayed in the same manner as that set forth above for the assessment of stimulation of chondrocytes, except using synovial linings of the radiocarpal joints from 5-7-year-old dairy cows dissected under sterile conditions as the source of the cells.
- the synovial membrane is dissociated and the cells prepared and plated in the same manner as that set forth above for articular chondrocytes. 5.
- the factor of the invention has the following characteristics with respect to its ability to retain activity in the foregoing assays. a) Heating the factor at 60°C for one hour does not destroy activity.
- the TDCSF of the invention is prepared from thyroid tissue of any vertebrate source, including human, bovine, porcine, avian or ovine.
- a typical and convenient method begins with homogenization of human or bovine thyroid tissue to obtain a crude homogenate which is then centrifuged to obtain a supernatant. Centrifugation is at high g (about 30,000 g) for 30-60 minutes. The supernatant is then treated with a series of ammonium sulfate concentrations.
- ammonium sulfate at 40% saturation at pH 7.2 is added and the precipitate removed.
- the ammonium sulfate concentration is then brought to 80% saturation at pH 7.2, and the precipitate is recovered.
- the recovered precipitate is then redis- solved and dialyzed to remove the salts and subjected to chromatography on heparin-Sepharose.
- the column is equilibrated with 0.5 M NaCl, 25 mM Tris-HCl, pH 7.2, and 1 mM EDTA.
- the factor elutes from the column in 0.5 M NaCl.
- the column can then be washed with a slightly higher concentration of salt, typically 0.65 M NaCl.
- This partially purified factor has the characteristics of TDCSF as set forth above.
- the activity-containing fractions are pooled and dialyzed thoroughly against water containing 1 mM 2-ME, then lyophilized and stored at -20°C. If they are to be tested directly for activity they are dialyzed against DPBS with 1 mM 2-ME. Prior to assay the factor is suspended in DPBS containing 1 mM 2-ME.
- the factor may be stored in the presence of reducing agent (e.g., 1 mM 2-ME) for 1-2 years; activity is lost when the factor is stored even at -20°C for more than 6 months in the absence of reducing agent.
- reducing agent e.g. 1 mM 2-ME
- the dialyzed eluate from the heparin-Sepharose is subjected to Sephacryl S-300, which permits preparative separation of high molecular weight material from the remainder of the composition.
- the column is equilibrated with 1/10 DPBS containing 1 mM 2-ME.
- the factor elutes in the void volume when applied as described above, or when applied in the presence of 5 M or 8 M urea.
- the factor may be further purified in its complex or dissociated form by subjecting it to gel electrophoresis under nondenaturing conditions.
- the partially purified factor eluted from the heparin-Sepharose column or the further purified materials resulting from gel filtration can be used as immunogens to produce antibodies specific for the TDCSF of the invention.
- These antibodies are useful in assessing the levels of naturally occurring TDCSF in biological fluids using standard immunoassay techniques.
- the antibodies are prepared using conventional immunization protocols by injecting the preparation, in the presence of adjuvant if needed, into suitable mammalian subjects such as rabbits, mice or sheep in repeated immunization, and measuring the titers in the serum of the injected host using standard ELISA or RIA assays. When high titer serum is obtained, the serum can be harvested as a source of antibodies for immunoassays.
- the antibodies or their specifically immunoreactive fragments can be used in these assays.
- the nature of the protocols for immunoassays using enzyme, radioactive, or fluorescent labels is well known in the art.
- antibody conjugated to solid support can be used to purify TDCSF by affinity chromatography.
- monoclonal antibodies can be prepared to the TDCSF of the invention by harvesting the spleens, for example, of the immunized animals and immortalizing these cells by hybridization or viral infection. Immortalized cells secreting the desired antibodies are identified by subjecting the supernatants to immunoassays using the partially purified TDCSF of the invention as an antigen. Antibody-secreting colonies are then cultured n vitro or in ascites fluid.
- the factor may also be prepared as a conjugate with solid support, label or other effector molecule to take advantage of the ability of the factor to target chondrocytes and synovial fibroblasts.
- Label or an effector molecule which modifies the metabolism of the target cell can be coupled to the factor of the invention using standard coupling technology to deliver the label or effector to the target, or to bind target to solid support.
- uncontrolled growth of articular chondrocytes could be controlled by delivery of toxins to these cells using TDSCF conjugated to poisons such as ricin A or diphtheria toxin.
- cells whose metabolism is affected by the TDCSF of the invention can be labeled and localized using the factor coupled to radioactive or fluorescent label.
- the factor may be coupled to solid supports, and used as an affinity column for the purification of the antibodies prepared as described above or for purification and isolation of populations of cells containing receptors specifically reactive with TDCSF.
- the factor of the invention is useful in stimulating the growth of chondrocytes and synovial fibroblasts both in vitro and in vivo.
- the factor can be used as a serum substitute in the culture of these cells. Accordingly, both chondrocytes and synovial fibroblasts may be grown under serum-free conditions when the factor of the invention is added to the culture at concentrations on the order of 200 ⁇ g/ml culture medium (for the material purified approximately 5-fold from thyroid homogenate) .
- the factor of the invention is useful in developing cartilage implants for joint repair in vitro.
- chondrocytes are cultured to confluence using culture medium as described above on a preparative basis.
- a matrix may also be supplied to aid in the aggregation of the chondrocytes.
- the factor is supplied at concentrations comparable to those useful for in vitro culture in general, as described above.
- the resulting implants can also be used in bone and tissue repair and additional amounts of the factor can be added to the implants in order to stimulate grafting to the surrounding tissue.
- Means to surgically implant such matrices into the skeletal system are understood in the art.
- the factors of the invention can be administered in standard pharmaceutical compositions either locally or systemically to stimulate cartilage repair and to maintain tissues under conditions of trauma or degenerative joint disease.
- subjects to which 10 the factor of the invention could usefully be administered are those suffering from osteoporosis, bone fractures, degenerative diseases of the cartilage, or patients who have been supplied grafts which are coated with synovial fibroblasts or chondrocytes to aid in 15 grafting.
- the TDCSF of the invention can be administered directly to affected tissue by lavage to the joints.
- Example 1 Preparation and Purification of Chondrocvte-Stimulating Factor from Thyroid Tissue
- a modification of the method to isolate 25 prostate epithelial cell growth factor from bovine brain was used.
- bovine thyroid tissue 45 g was homogenized in 450 ml of 0.15 M NaCl 30 (pH 7.0), containing 0.25 mM phenylmethylsulfonyl fluoride, 1 mM EDTA and 1 ⁇ g/ml of pepstatin, using a tissue blender and a Polytron tissue homogenizer (setting of 5, for 10 min, Model PT10, Brinkmann Instruments, Inc. , Lucerne, Switzerland) . The homogenate was 35 centrifuged for 45 min at 30,000 x g, and the supernatant was precipitated with ammonium sulfate at 40% and at 80% saturation, pH 7.2.
- the 40% precipitate was suspended in 100 ml of water, and the 80% precipitate was suspended in 36 ml of water. Both precipitates were dialyzed against 20 liters of water, with frequent changes over a 60-hour period. These dialyzed solutions were tested for ability to stimulate growth of articular chondrocytes as described above. The 80% precipitate showed activity, the 40% precipitate did not. Portions of the homogenate and of the ammonium sulfate fraction precipitating between 40-80% saturation at pH 7.2 showed comparable activity in terms of total cpm calculated for the total sample, as shown in Table 1. About one-third of the total protein, but all the activity, was recovered in the 40-80% precipitate.
- the dialyzed and lyophilized eluate could not be stored for more than six months at -20°C; however, when 1 mM ⁇ -mercaptoethanol (2-ME) was added, the activity was stabilized so that it was retained over a two-year period.
- the DTT-treated, HOAc-treated and trypsin- treated samples were dialyzed against 2 1 of DPBS containing 1 mM 2-ME over 24 hours using a dialysis tubing of pore size 1.2-2 kd before testing in the assay.
- S-300 which has a molecular weight cutoff of 10 4-106 daltons.
- a 2.5 x 41.0 cm S-300 column was equilibrated with 1/10 DPBS containing 1 mM 2-ME.
- Four ml of the 0.5 M NaCl heparin-Sepharose eluate was added to the column; the column was then washed in the equilibration buffer.
- this same S-300 column equili- brated in 1/10 DPBS containing 1 mM 2-ME, was used to run aliquots of the 0.5 M NaCl heparin-Sepharose eluate treated with 5 M and 8 M urea prior to column loading, taking into consideration secondary volume changes.
- the flow rate was 1 ml/min with all three columns. Five ml fractions were collected for both the untreated and 5 M urea-treated samples while 3 ml fractions were collected for the 8 M urea-treated sample. Fractions were added directly to articular chondrocytes for assay as described above. Protein was determined by absorbance at 280 nm.
- Table 1 above shows the effect of the Sephacryl S-300 fractionation on purification. Treatment with the Sephacryl column generally resulted in a modest increase in specific activity.
- SDS- PAGE SDS polyacrylamide gel electrophoresis
- nondenaturing discontinuous (native) gel electrophoresis was performed according to the method of Ha es, B.D., et al., "Gel Electrophoresis of Proteins: A Practical Approach" (1981) IPI Press, Ltd., London and Washington, D.C., page 13. Approximately 5-15 ⁇ g of protein were run on each gel.
- Lane 1 is the fraction eluting at 75-79 ml from the column run without pretreating the eluate with urea. This developed gel shows a highly stained, high molecular weight region at the top of the gel and a band at 660 kd which is identified as thyroglobulin.
- Lane 2 represents a comparable fraction (elution volume, 85-89 ml) from the 5 M urea-treated eluate, and shows only the high molecular weight band.
- Lane 3 shows the results of the corresponding eluate from the column wherein 8 M urea treatment had been used; it shows a relative loss of intensity at the top of the gel in comparison to lane 2 and the production of two diffuse intensely stained regions. There are no lower molecular weight components on the gel.
- Example 5 Exclusion of Alternative Factors As stated hereinabove, it is known that none of T 3 , T 4 and calcitonin stimulate the growth of articular chondrocytes in the absence of serum; hence, these addi ⁇ tional components of thyroid tissue cannot be responsible for the activity of the newly isolated factor. Thyro- globulin was tested directly in the chondrocyte assay described above and found to be inactive. Factors generally known which do have the ability to stimulate articular chondrocytes are also shown to be different from the factor of the invention.
- fibroblast growth factor both the acidic and basic forms, elute from heparin- Sepharose at a considerably higher salt concentration than does TDCSF.
- the elution of the factor of the invention at a lower concentration cannot be explained as the prevention of binding to the heparin-Sepharose by a prior complexation with heparin, as conditions designed to decouple this complex fail to liberate any factor from the preparation which behaves as FGF.
- antibodies immunoreactive with FGF do not cross-react with the thyroid derived chondrocyte-stimulating factor of the invention using immunoblot techniques.
- IGF-I Insulin-like growth factor I
- IGF-I Insulin-like growth factor I
- a binding protein of either 150 kd or 40 kd, both molecular weights much lower than that associated with the TDCSF of the invention.
- IGF-I is known to be stable to acid, unlike the TDCSF.
- IGF-II is reported to be similar to IGF-I.
- Epidermal growth factor also is of low molecular weight and requires intramolecular disulfide bonds for activity. Hence, EGF is inactive in the presence of disulfide reducing agents, unlike the factor of the invention. Furthermore, EGF is known to be stable to acids. Antibodies prepared against EGF do not cross- react with the TDCSF; in addition, anti-EGF does not inhibit the stimulatory activity of the thyroid-derived factor described herein.
- TGF- ⁇ is also a low molecular weight molecule which is, unlike the present factor, stable to acid. TGF- ⁇ also requires disulfide linkages for activity and is unstable to reducing agents capable of reducing the disulfide to sulfhydryl groups.
- PDGF can be distinguished from the thyroid-derived factor of the invention by virtue of its inactivity in the presence of disulfide reducing agents.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Thyroid-derived chondrocyte stimulating factor (TDCSF) is a high molecular weight complex (greater than 500 kd) of proteinaceous subunits which can be at least partially dissociated into active portions by 8 M urea. TDCSF stimulates articular chondrocyte and synovial fibroblast growth under serum-free conditions. TDCSF is useful for the culture of chondrocytes and fibroblasts in vitro as a serum substitute; for developing cartilage implants in vitro; and for in vivo use in cartilage and bone defect repair and degenerative joint diseases. TDCSF is stabilized in the presence of reducing agents for disulfide bonds. Antibodies for and conjugates of TDCSF are also disclosed.
Description
THYROID-DERIVED CHONDROCYTE-STI ULATING FACTOR
Technical Field
The invention relates to a factor useful for cartilage repair including in vitro stimulation of chondrocytes and synovial fibroblasts. More particu¬ larly, it concerns a factor which can be isolated from thyroid tissue which stimulates both synovial fibroblasts and chondrocytes under serum-free conditions and which is stabilized by reducing agents that reduce disulfides.
Background and Related Art
A number of factors are known that stimulate the growth of various cells under a variety of condi¬ tions. Most closely related to the factor disclosed herein in their activities with regard to the cells characterizing the bony and connective tissues are those which have a stimulatory effect on articular chondro¬ cytes. These include transforming growth factor β (TGF-β) , platelet derived growth factor (PDGF) , insulin- like growth factors types I and II (IGF-I and IGF-II) , acidic and basic fibroblast growth factors (FGF) and epidermal derived growth factor (EGF) . (Cohen, S. , et al., Adv Metab Disord (1975) S..265-284; Froesch, E.R. , et al., Ann Rev Phvsiol (1985) .42:443-467; Gospodarowicz, D. , et al.. Endocrine Reviews (1987) 8.:95-114; McQuillan, D.J., et al., Biochem J (1986) 240;423-430; Ross, R. , et al.. Cell (1986) 46..155-169; Smith, R.L., et al. , J Orthop Res (1989) 2:198-207; Tucker, R.F., et al.. Cancer Res (1983) .43:1581-1586.
The known thyroid hormones, 3,3* ,5'-triiodo- 1,3-L-thyronine (T3) ; thyroxine (T4) and calcitonin are known to affect connective tissue metabolism. However, their effects are generally directed to immature cells. T-, and T. are important for growth and maturation of the epithelial cartilage secondary ossification, and generalized skeletal development; calcitonin increases hypertrophy and maturation of embryonic and growth plate cartilage, but resting cartilage is unresponsive to calcitonin.
In a recent publication, applicants disclosed the presence of an activity in partially purified thyroid calcitonin which provided stimulation of adult articular chondrocyte proliferation and glycosaminoglycan synthesis under serum-free conditions—conditions wherein none of T3, T, or calcitonin provide such stimulation. In this paper, Jones, D.G. and Smith, R.L., J Orthoped Res (1990) 8>:227-233, the disclosure of which is incorporated herein by reference, the authors disclosed that this activity could be eluted from heparin-Sepharose at low salt concentration (0.5 M NaCl)—conditions under which the fibroblast growth factors, known to stimulate articular chondrocyte proliferation under similar conditions, are not eluted from this support. Acidic FGF is eluted at 1 M NaCl under comparable conditions and basic FGF is eluted at 1.6 M NaCl under comparable conditions (Lobb, R.R. , et al., Anal Bioche (1986) 154:1-14.) The nature of this activity was not further characterized.
It has now been found that the chondrocyte stimulating activity obtainable from thyroid tissue is associated with a complex of high molecular weight components which can be prepared in isolated and purified form. The invention herein thus provides a new factor for the stimulation of connective tissue growth.
Disclosure of the Invention
The invention provides a complex of high molecular weight which can be at least partially dissociated by 8M urea into active subunits. Both the complex and the dissociated subunits stimulate chondro¬ cyte and synovial fibroblast growth under serum-free conditions in vitro and can thus be used as a substitute for serum in the culture of these cells. Furthermore, the complex or its dissociated portions are useful in the in vitro development of implants for medical use, and are useful in vivo in the treatment of connective tissue conditions which reguire the enhancement of connective tissue growth and/or the integration of grafts or implants into bone or cartilage. Thus, in one aspect, the invention is directed to a high molecular weight proteinaceous complex with the ability to stimulate chondrocyte or synovial fibroblast growth under serum-free conditions in vitro. The complex can be at least partially dissociated by 8 M urea into portions of the complex which retain this activity but which are also of high molecular weight (>500 kd) . The invention is also directed to these subunits. The complex and its subunits, collectively called thyroid- derived chondrocyte stimulating factor (TDCSF) , are stabilized by reducing agents that are capable of reducing disulfide bonds, such as ercaptoethanol and dithiothreitol. They are (the factor is) inactivated by treatment with acetic acid for one hour at 4°C, and by treatment by trypsin. The complex and its subunits are also inactivated by heating to 100°C for one hour but not by heating to 60°C for one hour. The factor can be eluted from heparin-Sepharose at 0.5 M NaCl.
In additional aspects, the invention is directed to pharmaceutical compositions, including implant compositions containing this factor and to
methods for treating diseases or degenerative conditions of the connective tissue system with the factor or its compositions. In addition, the invention is directed to a method to obtain the factor from thyroid tissue and to methods to use the factor in vitro in the development of implant compositions or as a serum substitute in the growth of chondrocytes or fibroblasts. The invention is also directed to antibodies specifically immunoreactive with the factor, and to conjugates of the factor with label or other effector agents, and to the uses of these antibodies and conjugates.
Brief Description of the Drawings
Figure 1 shows the elution pattern for the factor of the invention from a Sephacryl S-300 column.
Figure 2 shows an elution pattern analogous to that of Figure 1, but with the inclusion of 5 M urea.
Figure 3 shows an elution pattern analogous to that of Figures 1 and 2, but in the presence of 8 M urea. Figure 4 shows the results of nonreducing native gel electrophoresis of the excluded volume shown in the elution patterns of Figures 1, 2 and 3.
Modes of Carrying Out the Invention The invention factor can be isolated from thyroid tissue and is provided as a high molecular weight complex of >500 kd. The complex can be at least partially dissociated by 8 M urea into subunits which retain the activity of the complex, and are also of high molecular weight. As used herein, the "factor" (TDCSF) of the invention includes both the complex in undisso- ciated form and the dissociated subunits, as described above. Both of these manifestations of the factor are capable of stimulating the growth of synovial fibroblasts
and adult articular chondrocytes under serum-free conditions.
The factor can be obtained from thyroid tissue by subjecting the 40-80% ammonium sulfate fraction from the tissue homogenate supernatant to chro atography on heparin-Sepharose. The factor elutes at approximately 0.5 M NaCl and is dialyzed against DPBS containing 1 mM 2-ME before testing. Any samples to be stored are dialyzed against water containing 1 mM 2-ME and freeze- dried. The factor can be further purified by gel filtration. In the gel filtration treatment, the factor is excluded from a Sephacryl S-300 column with a molecular weight cutoff of 10 -10 daltons. The factor can be further purified, if desired, using native gel electrophoresis.
The isolated and purified factor has the following characteristics:
1. The complex form of the factor is at least partially dissociated by 8 M urea into subunits which retain the characteristics of the complex listed below.
2. The factor is acidic—i.e., it does not bind to weak (carboxymethylcellulose) or strong (mono-S) cationic exchange columns at pH 7.2, but does bind to weak (DEAE cellulose) or strong (mono-Q) anion exchange columns at pH 7.2 under the following conditions: the candidate is applied to a column containing the anion or cation exchanger in the presence of 1/10 Dulbecco's phosphate-buffered saline (DPBS) at pH 7.2 in the presence of 1 mM β-mercaptoethanol (2-ME) . The ion exchange resin has been preeguilibrated in 1/10 DPBS. The presence or absence of the candidate in the flowthrough volume is then assessed. The ion exchange resins can then be eluted in salt gradient to verify presence or absence of the candidate in the eluate.
3. The factor of the invention stimulates the growth of chondrocytes in the following assay.
Adult articular chondrocytes are prepared by collecting bovine cartilage from radiocarpal joints and dissociated in 20 ml Dulbecco's Modified Eagle's Medium (DMEM) containing gentamicin (50 μg/ml) and bacterial collagenase (CLS-II and CLS-IV) , at a concentration of 0.5 g/ml each (Kohatsu, N.D., et al., "Transactions of the 27th Annual Meeting of the Orthopedic Research Society" (1981), 6.:214). The dissociated cells are collected by centrifugation at 450 g for 15 minutes and washed twice in DPBS and once in DMEM. Single cells are obtained by Nytex filtration and cell numbers determined by counting in a hemacytometer, and viability is assessed by Trypan Blue dye exclusion. After dilution in serum- free medium, the cells are dispersed in 16-mm plastic wells (24 wells/plate) at a density of 2 x 10 5 cells/cm_"> and incubated at 7% C02, 100% humidity, at 37°C. The medium consists of DMEM and Ham's F-12 medium mixed at a ratio of 1:1; the sulfate concentration of this mixture is 78.6 mg/1. Gentamicin (50 μg/ml), selenium (2 x 10 —8 M) , and a lipid supplement (Bettger, .J., et al. , Proc Natl Acad Sci USA (1981) 21:5588-5592) were also added. These lipids are transferred to the medium as liposomes prepared just prior to use, as described in the Jones and Smith paper referenced above ( J Orthop Res (1990) 8.:227- 233). Prior to use, the stock liposomes are diluted 1:1 in DMEM and the mixture is sonicated for 3 minutes at 4°C under nitrogen and sterilized by ultrafiltration (0.22 μm) . Culture dishes are treated with poly-D-lysine (0.1 mg/ml) before plating the cells under these serum-free conditions; polylysine is removed by repeated rinsing with sterile distilled water (3 x 1 ml/well) .
The foregoing culture medium is changed every three days and gentamicin (50 μg/ml) is maintained in all culture conditions. Each well contains 0.5 ml of medium. In the assay itself, tritiated thymidine (methyl-3H-thymidine, 27.7 Ci/g) is added to the medium at 0.5 μCi/well, and the wells are incubated in the presence of the labeled thymidine for 72 hours at 37°C. The medium is then removed from each well and the cell layer gently rinsed twice with 1 ml DPBS to remove unincorporated thymidine. The cells are solubilized by addition of 0.5 ml 1 N sodium hydroxide and heating at 60°C for one hour. The solubilized samples are then counted.
4. The TDCSF of the invention stimulates the growth of synovial fibroblasts. The ability of the factor to stimulate the growth of synovial fibroblasts is assayed in the same manner as that set forth above for the assessment of stimulation of chondrocytes, except using synovial linings of the radiocarpal joints from 5-7-year-old dairy cows dissected under sterile conditions as the source of the cells. The synovial membrane is dissociated and the cells prepared and plated in the same manner as that set forth above for articular chondrocytes. 5. The factor of the invention has the following characteristics with respect to its ability to retain activity in the foregoing assays. a) Heating the factor at 60°C for one hour does not destroy activity. b) Heating the factor to 100°C for one hour does destroy activity. c) Treating the factor in the presence of 1 mM 2-mercaptoethanol (2-ME) in DPBS with trypsin (100 μg/ml) for 30 minutes at 25°C, whereupon the reaction is stopped with trypsin inhibitor (100 μg/ml) destroys activity.
d) Treating the factor in the presence of 1 mM 2-mercaptoethanol (2-ME) in DPBS with 0.1 M dithio- • threitol (DTT) at 22°C for 30 minutes does not destroy activity. e) Treating the factor in the presence of 1 mM
2-ME in DPBS in the presence of 1 M acetic acid at 4°C for 30 minutes destroys activity.
The factors in the latter three conditions are first dialyzed against DPBS with 1 mM 2-ME for 24 hours (using dialysis tubing of 1.2-2 kd) before testing for activity.
Using the foregoing criteria, the character¬ istics of the factors of the invention can be confirmed and verified.
Method of Preparation
The TDCSF of the invention is prepared from thyroid tissue of any vertebrate source, including human, bovine, porcine, avian or ovine. A typical and convenient method begins with homogenization of human or bovine thyroid tissue to obtain a crude homogenate which is then centrifuged to obtain a supernatant. Centrifugation is at high g (about 30,000 g) for 30-60 minutes. The supernatant is then treated with a series of ammonium sulfate concentrations.
In a typical procedure, ammonium sulfate at 40% saturation at pH 7.2 is added and the precipitate removed. The ammonium sulfate concentration is then brought to 80% saturation at pH 7.2, and the precipitate is recovered. The recovered precipitate is then redis- solved and dialyzed to remove the salts and subjected to chromatography on heparin-Sepharose.
The column is equilibrated with 0.5 M NaCl, 25 mM Tris-HCl, pH 7.2, and 1 mM EDTA. The factor elutes from the column in 0.5 M NaCl. The column can then be
washed with a slightly higher concentration of salt, typically 0.65 M NaCl.
This partially purified factor has the characteristics of TDCSF as set forth above. The activity-containing fractions are pooled and dialyzed thoroughly against water containing 1 mM 2-ME, then lyophilized and stored at -20°C. If they are to be tested directly for activity they are dialyzed against DPBS with 1 mM 2-ME. Prior to assay the factor is suspended in DPBS containing 1 mM 2-ME.
The factor may be stored in the presence of reducing agent (e.g., 1 mM 2-ME) for 1-2 years; activity is lost when the factor is stored even at -20°C for more than 6 months in the absence of reducing agent. in further purification, the dialyzed eluate from the heparin-Sepharose is subjected to Sephacryl S-300, which permits preparative separation of high molecular weight material from the remainder of the composition. The column is equilibrated with 1/10 DPBS containing 1 mM 2-ME. The factor elutes in the void volume when applied as described above, or when applied in the presence of 5 M or 8 M urea.
The factor may be further purified in its complex or dissociated form by subjecting it to gel electrophoresis under nondenaturing conditions.
Preparation of Antibodies
The partially purified factor eluted from the heparin-Sepharose column or the further purified materials resulting from gel filtration can be used as immunogens to produce antibodies specific for the TDCSF of the invention. These antibodies are useful in assessing the levels of naturally occurring TDCSF in biological fluids using standard immunoassay techniques. The antibodies are prepared using conventional
immunization protocols by injecting the preparation, in the presence of adjuvant if needed, into suitable mammalian subjects such as rabbits, mice or sheep in repeated immunization, and measuring the titers in the serum of the injected host using standard ELISA or RIA assays. When high titer serum is obtained, the serum can be harvested as a source of antibodies for immunoassays. The antibodies or their specifically immunoreactive fragments, such as the Fab, Fab1 or F(ab) '2 can be used in these assays. The nature of the protocols for immunoassays using enzyme, radioactive, or fluorescent labels is well known in the art. In addition, antibody conjugated to solid support can be used to purify TDCSF by affinity chromatography. In addition to the preparation of polyclonal antisera, monoclonal antibodies can be prepared to the TDCSF of the invention by harvesting the spleens, for example, of the immunized animals and immortalizing these cells by hybridization or viral infection. Immortalized cells secreting the desired antibodies are identified by subjecting the supernatants to immunoassays using the partially purified TDCSF of the invention as an antigen. Antibody-secreting colonies are then cultured n vitro or in ascites fluid.
Conjugates of the Factor
The factor may also be prepared as a conjugate with solid support, label or other effector molecule to take advantage of the ability of the factor to target chondrocytes and synovial fibroblasts. Label or an effector molecule which modifies the metabolism of the target cell can be coupled to the factor of the invention using standard coupling technology to deliver the label or effector to the target, or to bind target to solid support.
For example, uncontrolled growth of articular chondrocytes could be controlled by delivery of toxins to these cells using TDSCF conjugated to poisons such as ricin A or diphtheria toxin. In addition, cells whose metabolism is affected by the TDCSF of the invention can be labeled and localized using the factor coupled to radioactive or fluorescent label. In addition, the factor may be coupled to solid supports, and used as an affinity column for the purification of the antibodies prepared as described above or for purification and isolation of populations of cells containing receptors specifically reactive with TDCSF.
Utility and Administration The factor of the invention is useful in stimulating the growth of chondrocytes and synovial fibroblasts both in vitro and in vivo.
First, as is apparent from the assay set forth above, the factor can be used as a serum substitute in the culture of these cells. Accordingly, both chondrocytes and synovial fibroblasts may be grown under serum-free conditions when the factor of the invention is added to the culture at concentrations on the order of 200 μg/ml culture medium (for the material purified approximately 5-fold from thyroid homogenate) .
In addition, the factor of the invention is useful in developing cartilage implants for joint repair in vitro. In such implants, chondrocytes are cultured to confluence using culture medium as described above on a preparative basis. A matrix may also be supplied to aid in the aggregation of the chondrocytes. The factor is supplied at concentrations comparable to those useful for in vitro culture in general, as described above.
The resulting implants can also be used in bone and tissue repair and additional amounts of the factor
can be added to the implants in order to stimulate grafting to the surrounding tissue. Means to surgically implant such matrices into the skeletal system are understood in the art. 5 Further, the factors of the invention can be administered in standard pharmaceutical compositions either locally or systemically to stimulate cartilage repair and to maintain tissues under conditions of trauma or degenerative joint disease. Thus, subjects to which 10 the factor of the invention could usefully be administered are those suffering from osteoporosis, bone fractures, degenerative diseases of the cartilage, or patients who have been supplied grafts which are coated with synovial fibroblasts or chondrocytes to aid in 15 grafting. Preferably the TDCSF of the invention can be administered directly to affected tissue by lavage to the joints.
The following examples are intended to illustrate but not to limit the invention. 20
Example 1 Preparation and Purification of Chondrocvte-Stimulating Factor from Thyroid Tissue A modification of the method to isolate 25 prostate epithelial cell growth factor from bovine brain (Crabb, J.W. , et al., Biochem Biophys Res Comm (1986) .13.5:1155-1161; McKeehan, W.L., et al., Anal Biochem (1987) 164:563-569) was used. Briefly, bovine thyroid tissue (45 g) was homogenized in 450 ml of 0.15 M NaCl 30 (pH 7.0), containing 0.25 mM phenylmethylsulfonyl fluoride, 1 mM EDTA and 1 μg/ml of pepstatin, using a tissue blender and a Polytron tissue homogenizer (setting of 5, for 10 min, Model PT10, Brinkmann Instruments, Inc. , Lucerne, Switzerland) . The homogenate was 35 centrifuged for 45 min at 30,000 x g, and the supernatant
was precipitated with ammonium sulfate at 40% and at 80% saturation, pH 7.2. The 40% precipitate was suspended in 100 ml of water, and the 80% precipitate was suspended in 36 ml of water. Both precipitates were dialyzed against 20 liters of water, with frequent changes over a 60-hour period. These dialyzed solutions were tested for ability to stimulate growth of articular chondrocytes as described above. The 80% precipitate showed activity, the 40% precipitate did not. Portions of the homogenate and of the ammonium sulfate fraction precipitating between 40-80% saturation at pH 7.2 showed comparable activity in terms of total cpm calculated for the total sample, as shown in Table 1. About one-third of the total protein, but all the activity, was recovered in the 40-80% precipitate.
In further purification, 5 ml of the 80% dialyzed ammonium sulfate fraction (23.5 mg of protein) was added to a 1.5 x 22.0 cm heparin-Sepharose (Pharmacia) column equilibrated with 0.5 M NaCl, 25 mM Tris-HCl (pH 7.2) and 1 mM EDTA. The column was washed with approximately two volumes (80 ml) of equilibration buffer. Fractions in the eluate which contained protein, as determined by UV absorbance (280 nm) , were pooled. The column was then washed with 80 ml of a 0.65 M NaCl, 25 mM Tris-HCl (pH 7.2) and 1 mM EDTA solution and 80 ml of a 2.0 M NaCl, 25 mM Tris-HCl (pH 7.2) and 1 mM EDTA solution. Following both washes each eluate was pooled and the UV absorbances (280 nm) were measured and found to be below 0.10. Each of the three eluates were dialyzed against
16 liters of H-0 with changes every 12 hours, for a period of 48 hours, then lyophilized overnight to dryness, resuspended in 50 ml of water, and stored at -20°C. Final protein determinations were made using the Bio-Rad Protein Assay (Bio-Rad Laboratories, Richmond,
CA) . For storage, the eluates should be freeze-dried in the presence of 1 mM 2-ME. Neither the 0.65 M NaCl nor the 2.0 M NaCl eluates contained activity in this assay; however, the fraction removed at 0.5 M NaCl showed retention of total activity and most of the protein. These results are also shown in Table 1.
Table I
Purification of Thyroid-Derived Chondrocyte
Stimulation Activity
Total Total Total Total Fold
Sample Volume(ml) Protein(mg) Activity(cpm) Activity(cpm/mg) Purified
Sephacryl S-300 Fractionation No Urea 5 10 44 X 10' 44 X 10*" 7
5M Urea 5 22 73 X 10 33 X 10' 5
8M Urea 3 6 28 X 10' 46 X 10" 7
The results of further purification on Sephacryl S-300 are discussed below.
Example 2 Characterization of the 0.5 M Dialyzed Eluate
The dialyzed and lyophilized eluate could not be stored for more than six months at -20°C; however, when 1 mM β-mercaptoethanol (2-ME) was added, the activity was stabilized so that it was retained over a two-year period.
A. The eluate was treated with 2 M NaCl for 1 hour and size-fractionated with a Centricron-30 microconcentrator having a membrane pore size of 30 kd. All of the activity was shown to be in the retentate, thus indicating that the active factor is not an FGF heparin complex (this would have dissociated in 2 M salt) , which might prevent heparin-Sepharose binding.
B. The eluate failed to bind either weak or strong cation exchange columns, but did bind both weak and strong anion exchange columns when tested as set forth above. Treatment of the eluate on anion exchange resulted in dispersion of activity as a broad peak over gradient sodium chloride elution.
C. The eluate was also tested for its ability to stimulate labeled thymidine uptake by synovial fibro¬ blasts and shown to cause a 2.4-fold increase in uptake with the eluate used in excess. As a positive control, bFGF at 1 μg/ml produced an approximately equal increase in uptake. D. There was a decrease in the activity in stimulating chondrocytes by the dialyzed eluate (404 cpm) when compared to the eluate alone wherein the resuspended factor had been diluted 1:1 with DPBS containing l mM 2-ME (903 cpm) but which was still significant as compared to control (174 cpm) .
E. Further tests were conducted by combining 1 ml DPBS buffer containing 1 mM 2-ME with 1 ml of the dialyzed and resuspended 0.5 M NaCl heparin-Sepharose eluate and testing the diluted solution. i) When 500 μl of this solution was adjusted to 0.1 M DTT and maintained at 22°C for 30 minutes, no decrease in activity was shown in the chondrocyte assay; indeed, the incorporation was slightly higher (526 cpm) than the dialyzed eluate. ii) An equal volume of the 1:1 dilution was adjusted to 1 N acetic acid and maintained at 4°C for 30 minutes, and then tested in the assay; the uptake of radioactivity when the treated eluate was tested was comparable to control (238 cpm) . iii) An addition 500 μl of the 1:1 dilution was treated with 100 μg/ml trypsin for 30 minutes at 25°C, and then stopped with 100 μg/ml trypsin inhibitor. This dropped the measured incorporation when the resultant was tested to 208 cpm, again insignificant. The DTT-treated, HOAc-treated and trypsin- treated samples were dialyzed against 2 1 of DPBS containing 1 mM 2-ME over 24 hours using a dialysis tubing of pore size 1.2-2 kd before testing in the assay.
F. Two 50 μl samples of the dialyzed and resuspended 0.5 M NaCl eluate were heated at 60°C and
100°C respectively for 1 hour. The sample heated to 100°C showed cpm uptake comparable to control; the 60°C treated sample showed an uptake of approximately 400 cpm.
Example 3
Further Purification of the 0.5 M NaCl Eluate The 0.5 M NaCl eluate from the heparin- Sepharose column was further purified using Sephacryl
S-300, which has a molecular weight cutoff of 10 4-106 daltons. A 2.5 x 41.0 cm S-300 column was equilibrated
with 1/10 DPBS containing 1 mM 2-ME. Four ml of the 0.5 M NaCl heparin-Sepharose eluate was added to the column; the column was then washed in the equilibration buffer. In addition, this same S-300 column, equili- brated in 1/10 DPBS containing 1 mM 2-ME, was used to run aliquots of the 0.5 M NaCl heparin-Sepharose eluate treated with 5 M and 8 M urea prior to column loading, taking into consideration secondary volume changes. The flow rate was 1 ml/min with all three columns. Five ml fractions were collected for both the untreated and 5 M urea-treated samples while 3 ml fractions were collected for the 8 M urea-treated sample. Fractions were added directly to articular chondrocytes for assay as described above. Protein was determined by absorbance at 280 nm.
For the untreated eluate, the majority of stimulatory activity eluted at or near the Vo (65 ml) (Figure 1) . Adjustment of the eluate to 5 M urea prior to loading on this column did not shift the activity or protein profiles (Figure 2) . Adjustment of the eluate to 8 M urea provided the same initial peak at the Vo (Figure 3), but having a 1.9-fold increase in specific activity (46,000 cpm/mg) when compared to the specific activity of the 0.5 M NaCl heparin-Sepharose eluate (24,000 cpm/mg). Similar levels of specific activity were observed without treatment (44,000 cpm/mg) or with 5 M urea treatment (33,000 cpm/mg).
In all cases, a second peak of activity was observed at an elution volume of 115 ml; the second peak did not retain its stimulatory activity following storage at -20°C even in the presence of 2-ME.
Table 1 above shows the effect of the Sephacryl S-300 fractionation on purification. Treatment with the Sephacryl column generally resulted in a modest increase in specific activity.
Exa ple 4 Gel Electrophoresis SDS polyacrylamide gel electrophoresis (SDS- PAGE) was performed according to the method of Laemmli, U.K., Nature (1970) 227:680-685, and nondenaturing discontinuous (native) gel electrophoresis was performed according to the method of Ha es, B.D., et al., "Gel Electrophoresis of Proteins: A Practical Approach" (1981) IPI Press, Ltd., London and Washington, D.C., page 13. Approximately 5-15 μg of protein were run on each gel.
The peaks from the Sephacryl S-300 columns containing the major activity were subjected to native PAGE on a 5% gel, and the gel was developed by Coomassie staining. The results are shown in Figure 4.
Lane 1 is the fraction eluting at 75-79 ml from the column run without pretreating the eluate with urea. This developed gel shows a highly stained, high molecular weight region at the top of the gel and a band at 660 kd which is identified as thyroglobulin.
Lane 2 represents a comparable fraction (elution volume, 85-89 ml) from the 5 M urea-treated eluate, and shows only the high molecular weight band. Lane 3 shows the results of the corresponding eluate from the column wherein 8 M urea treatment had been used; it shows a relative loss of intensity at the top of the gel in comparison to lane 2 and the production of two diffuse intensely stained regions. There are no lower molecular weight components on the gel. These results clearly demonstrate that the complex representing the factor of the invention undergoes at least partial dissociation, although there was no loss in activity, as set forth above.
Example 5 Exclusion of Alternative Factors As stated hereinabove, it is known that none of T3, T4 and calcitonin stimulate the growth of articular chondrocytes in the absence of serum; hence, these addi¬ tional components of thyroid tissue cannot be responsible for the activity of the newly isolated factor. Thyro- globulin was tested directly in the chondrocyte assay described above and found to be inactive. Factors generally known which do have the ability to stimulate articular chondrocytes are also shown to be different from the factor of the invention.
As set forth above, fibroblast growth factor, both the acidic and basic forms, elute from heparin- Sepharose at a considerably higher salt concentration than does TDCSF. The elution of the factor of the invention at a lower concentration cannot be explained as the prevention of binding to the heparin-Sepharose by a prior complexation with heparin, as conditions designed to decouple this complex fail to liberate any factor from the preparation which behaves as FGF. Furthermore, it has been demonstrated by applicants that antibodies immunoreactive with FGF do not cross-react with the thyroid derived chondrocyte-stimulating factor of the invention using immunoblot techniques.
Insulin-like growth factor I (IGF-I) has a molecular weight of only 7.5 kd and is complexed to a binding protein of either 150 kd or 40 kd, both molecular weights much lower than that associated with the TDCSF of the invention. Furthermore, IGF-I is known to be stable to acid, unlike the TDCSF. IGF-II is reported to be similar to IGF-I.
Epidermal growth factor (EGF) also is of low molecular weight and requires intramolecular disulfide bonds for activity. Hence, EGF is inactive in the
presence of disulfide reducing agents, unlike the factor of the invention. Furthermore, EGF is known to be stable to acids. Antibodies prepared against EGF do not cross- react with the TDCSF; in addition, anti-EGF does not inhibit the stimulatory activity of the thyroid-derived factor described herein.
TGF-β is also a low molecular weight molecule which is, unlike the present factor, stable to acid. TGF-β also requires disulfide linkages for activity and is unstable to reducing agents capable of reducing the disulfide to sulfhydryl groups.
Finally, PDGF can be distinguished from the thyroid-derived factor of the invention by virtue of its inactivity in the presence of disulfide reducing agents.
Claims
1. Thyroid-derived chondrocyte stimulating factor (TDCSF) in isolated and purified form which TDCSF is a proteinaceous complex or active subunit thereof; said complex or subunit having a molecular weight greater than 500 kd, and said complex at least partially dissociable into active subunits by 8 M urea; wherein said TDCSF stimulates the growth of adult chondrocytes and synovial fibroblasts under serum-free conditions; wherein said TDCSF is acidic, is sensitive to trypsin digestion, is inactivated by treating with 1 M acetic acid for 1 hour at 4° C and by treating at 100° C for one hour, but is not inactivated by treating at 60° C for one hour; wherein said TDCSF elutes from heparin- Sepharose at 0.5 M NaCl; and wherein said TDCSF is stabilized in the presence of reagents capable of reducing disulfide linkages.
2. The TDCSF of claim 1 which is obtained from mammalian thyroid tissue.
3. A method to prepare the TDSCF of claim 1 which method comprises; homogenizing thyroid tissue; removing particles form the homogenate to obtain a particle-free first supernatant; treating the supernatant with ammonium sulfate at 40% saturation to obtain a first precipitate and a second supernatant; recovering the second supernatant; treating the second supernatant with 80% saturation of ammonium sulfate, pH 7.2 to obtain a second precipitate and a third supernatant; redissolving said second precipitate and removing ammonium sulfate therefrom; treating said redissolved and desalted second precipitate with heparin-Sepharose under conditions wherein said TDCSF is adsorbed to the heparin-Sepharose; recovering the heparin-Sepharose containing the adsorbed TDCSF; and eluting the TDCSF from the heparin-Sepharose column.
4. The method of claim 3 wherein said eluting is conducted at 0.5 M NaCl, pH 7.2.
5. The method of claim 3 which further includes separating said TDCSF from substances of molecular weight less than 500 kd.
6. The method of claim 5 wherein said separation is conducted in the presence of a concentration of urea capable to at least partially dissociate said complex.
7. A pharmaceutical composition useful for stimulation of cartilage repair which composition comprises, as active ingredient, the TDCSF of claim 1 in admixture with a pharmaceutically acceptable excipient.
8. The pharmaceutical composition of claim 7 wherein said composition is a bone or joint implant.
9. A method to stimulate cartilage repair in a mammalian subject which method comprises administering to a subject in need of such treatment the TDCSF of claim 1 or a pharmaceutical thereof.
10. A method to develop cartilage implants in vitrof which method comprises treating a culture of adult chondrocytes with the TDCSF of claim 1 under conditions wherein said chondrocytes are aggregated to provide said implant; and recovering the implant from the culture.
10
11. The method of claim 10 wherein the culture further includes a matrix for the support of the implant.
12. A method to culture chondrocytes or 15 synovial fibroblasts in vitro which method comprises culturing said chondrocytes or fibroblasts in the presence of the TDCSF of claim 1 and in the presence of sufficiently low quantities of serum that absent the TDCSF of claim 1, growth would not be achieved. 20
13. Antibodies specifically immunoreactive with the TDCSF of claim 1.
14. The antibodies of claim 13 which are 25 polyclonal.
15. The antibodies of claim 14 which are monoclonal.
30 16. A method to determine the presence, absence or amount of the TDCSF of claim 1 which method comprises contacting a sample suspected of containing said TDCSF with antibodies' or fragments of antibodies specifically immunoreactive with said TDCSF under
35 conditions wherein a complex is formed between said antibodies or fragments and TDCSF; and detecting the presence, absence or amount of said complex.
17. A method to purify TDCSF which method comprises contacting a sample containing said TDCSF with the antibodies of claim 13 conjugated to solid support under conditions wherein TDCSF is adsorbed to said antibodies coupled to said support; and recovering the TDCSF from the support.
18. A conjugate which comprises the TDCSF of claim 1 coupled with an additional ligand selected from the group consisting of a label, solid support, and an effector moiety.
19. The conjugate of claim 18 wherein said ligand is a label.
20. A method to detect the presence of cells having specific receptors for TDCSF which method comprises contacting an environment suspected of containing said cells with the conjugate of claim 19; allowing the conjugate to home to said cells; and detecting the location of said conjugate.
21. The conjugate of claim 18 wherein said ligand is an effector moiety.
22. The conjugate of claim 21 wherein the effector moiety is a toxin.
23. A method to impair or destroy chondrocytes or fibroblasts which method comprises administering to an environment containing said chondrocytes or fibroblasts the conjugate of claim 22; and 5 allowing said conjugate to home to said chondrocytes or fibroblasts; wherein said toxin is delivered to said chondrocytes or fibroblasts.
10 24. The conjugate of claim 18 wherein said ligand is a solid support.
25. A method to purify antibodies specifically immunoreactive with TDCSF which method comprises 15 contacting a sample containing said antibodies with the conjugate of claim 24 under conditions wherein said antibodies are adsorbed to the support; and recovering the antibodies from the support.
20 26. A method to isolate a population of cells having, on their surface, a receptor specific for TDCSF, which method comprises contacting a sample containing said cells with the conjugate of claim 24 under conditions wherein said cells are adsorbed to the
25 support; and recovering the cells from said support.
27. A population of cells prepared by the method of claim 26.
30 28. A population of cells having, on their surface, a receptor specific for TDCSF.
35
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4508906A JPH06508111A (en) | 1991-02-13 | 1992-02-05 | Thyroid-derived chondrocyte stimulating factor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US654,965 | 1991-02-13 | ||
US07/654,965 US5284830A (en) | 1991-02-13 | 1991-02-13 | Thyroid-derived chondrocyte-stimulating factor |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1992014749A1 true WO1992014749A1 (en) | 1992-09-03 |
Family
ID=24626943
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1992/000993 WO1992014749A1 (en) | 1991-02-13 | 1992-02-05 | Thyroid-derived chondrocyte-stimulating factor |
Country Status (4)
Country | Link |
---|---|
US (2) | US5284830A (en) |
EP (1) | EP0572573A4 (en) |
JP (1) | JPH06508111A (en) |
WO (1) | WO1992014749A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5876452A (en) * | 1992-02-14 | 1999-03-02 | Board Of Regents, University Of Texas System | Biodegradable implant |
US6013853A (en) * | 1992-02-14 | 2000-01-11 | The University Of Texas System | Continuous release polymeric implant carrier |
WO2003048357A1 (en) * | 2001-12-04 | 2003-06-12 | Mitsubishi Pharma Corporation | Method of activating protein |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2339907T3 (en) * | 1995-03-29 | 2010-05-26 | Sapporo Breweries Ltd. | METHOD OF DETERMINATION OF BETA- (D) -GLUCANO. |
US6307087B1 (en) * | 1998-07-10 | 2001-10-23 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
DE19926083A1 (en) * | 1999-06-08 | 2000-12-14 | Universitaetsklinikum Freiburg | Biological joint construct |
US20060257393A1 (en) * | 2002-12-20 | 2006-11-16 | Kenji Sasaki | Method for protecting thiol group of protein |
US8697139B2 (en) | 2004-09-21 | 2014-04-15 | Frank M. Phillips | Method of intervertebral disc treatment using articular chondrocyte cells |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3652761A (en) * | 1969-09-04 | 1972-03-28 | Corning Glass Works | Immunochemical composites and antigen or antibody purification therewith |
US4356261A (en) * | 1980-04-22 | 1982-10-26 | Rush-Presbyterian-St. Luke's Medical Center | Anti-invasion factor containing cultures |
US4565789A (en) * | 1983-04-04 | 1986-01-21 | The United States Of America As Represented By The Department Of Health And Human Services | Cell matrix receptor system and use in cancer diagnosis and management |
ATE128715T1 (en) * | 1984-07-16 | 1995-10-15 | Celtrix Pharma | POLYPEPTIDE-INDUCING FACTORS IN BONE AND CARTILAGE. |
US4904259A (en) * | 1988-04-29 | 1990-02-27 | Samuel Itay | Compositions and methods for repair of cartilage and bone |
-
1991
- 1991-02-13 US US07/654,965 patent/US5284830A/en not_active Expired - Fee Related
-
1992
- 1992-02-05 JP JP4508906A patent/JPH06508111A/en active Pending
- 1992-02-05 WO PCT/US1992/000993 patent/WO1992014749A1/en not_active Application Discontinuation
- 1992-02-05 EP EP19920909353 patent/EP0572573A4/en not_active Withdrawn
-
1993
- 1993-11-12 US US08/152,224 patent/US5374550A/en not_active Expired - Fee Related
Non-Patent Citations (3)
Title |
---|
Clinical Research, Volume 37, No. 1, issued January 1989, JONES, D.G. et al., "Ammonium Sulfate Precipitation of Thyroid-Derived Cartilage Stimulating Factor", page 224A, entire document. * |
Connective Tissue Research, Volume 6, No. 1, issued 1978, MALEMUD, C.J. et al., "The Effect of Chondrocyte Growth Factor on Membrane Transport by Articular Chondrocytes in Monolayer Culture", pages 1-9. * |
See also references of EP0572573A4 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5876452A (en) * | 1992-02-14 | 1999-03-02 | Board Of Regents, University Of Texas System | Biodegradable implant |
US6013853A (en) * | 1992-02-14 | 2000-01-11 | The University Of Texas System | Continuous release polymeric implant carrier |
WO2003048357A1 (en) * | 2001-12-04 | 2003-06-12 | Mitsubishi Pharma Corporation | Method of activating protein |
Also Published As
Publication number | Publication date |
---|---|
US5374550A (en) | 1994-12-20 |
JPH06508111A (en) | 1994-09-14 |
EP0572573A1 (en) | 1993-12-08 |
US5284830A (en) | 1994-02-08 |
EP0572573A4 (en) | 1994-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4785079A (en) | Isolation of fibroblast growth factor | |
Clemmons et al. | Hormonal control of immunoreactive somatomedin production by cultured human fibroblasts | |
De Larco et al. | Sarcoma growth factor (SGF): specific binding to epidermal growth factor (EGF) membrane receptors | |
Deagen et al. | Determination of the distribution of selenium between glutathione peroxidase, selenoprotein P, and albumin in plasma | |
Farley et al. | Purification of a skeletal growth factor from human bone | |
Richmond et al. | Melanoma growth stimulatory activity: isolation from human melanoma tumors and characterization of tissue distribution | |
Vigny et al. | Specific binding of basic fibroblast growth factor to basement membrane‐like structures and to purified heparan sulfate proteoglycan of the EHS tumor | |
Jaffe et al. | Synthesis of antihemophilic factor antigen by cultured human endothelial cells | |
EP0159276B1 (en) | Substantially purified tumor growth inhibitory factor (tif) | |
CA1310902C (en) | Autocrine motility factors in cancer diagnosis and management | |
EP0148155B1 (en) | Osteogenic factors | |
Gospodarowicz et al. | Bovine brain and pituitary fibroblast growth factors: comparison of their abilities to support the proliferation of human and bovine vascular endothelial cells. | |
Gospodarowicz | Growth factors and their action in vivo and in vitro | |
Gertler et al. | Human growth hormone but not ovine or bovine growth hormones exhibits galactopoietic prolactin-like activity in organ culture from bovine lactating mammary gland | |
Zwiebel et al. | Partial purification of transforming growth factors from human milk | |
Thom et al. | Mechanisms of cellular adhesion: IV. Role of serum glycoproteins in fibroblast spreading on glass | |
Jacobs et al. | Characterization of growth factors derived from the rat ventral prostate | |
JP2648951B2 (en) | Human somatomedin carrier protein subunits and methods for their production | |
Keski-Oja et al. | Immunodetection and modulation of cellular growth with antibodies against native transforming growth factor-β | |
PT100313B (en) | ISOLATED OSTEOGENIC FACTOR, ITS OBTAINING PROCESS, OSTEOGENIC COMPOSITION AND ITS PREPARATION | |
Ballard et al. | The relationship between the insulin content and inhibitory effects of bovine colostrum on protein breakdown in cultured cells | |
EP0278781B1 (en) | Peptides with laminin activity | |
Choi et al. | Effect of platelet lysate on growth and sulfated glycosaminoglycan synthesis in articular chondrocyte cultures | |
US5284830A (en) | Thyroid-derived chondrocyte-stimulating factor | |
US4902782A (en) | Isolation of fibroblast growth factor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1992909353 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1992909353 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1992909353 Country of ref document: EP |